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Abstract
Background: Human antibacterial exposure occur in different ways including consumption of animal and
agricultural products as well as use of prescribed and non-prescribed agents. We estimated the prevalence and
explored the predictors of antibacterial use among patients presenting to hospitals in northern Uganda.
Methods: Four hundred fifty (450) patients were randomly selected and antibacterial use prior to hospital visit
measured using a questionnaire and urine antibacterial activity assay. Urine antibacterial bioassays were performed
using American type culture collections of Escherichia coli, Bacillus subtilis and Streptococcus pyogenes. Data were
analysed using STATA 12.0 at 95 % confidence level.
Results: Of 450 patients interviewed, 62.2 % had used antibacterial agents. Urine antibacterial activity was detected
in 30.4 % of the samples tested. Of the 85 patients who reported not taking any antibacterial at home, 16 (18.8 %)
had urine with antibacterial activity. Most test bacteria, E. coli (74.5 %), B. subtilis (72.6 %) and S. pyogens (86.7 %)
were sensitive to urine of patients who reported using antibacterial drugs before hospital visit. From the interview,
metronidazole 15.6 % (70/450), amoxicillin 12 % (54/450), and ciprofloxacin 10.4 % (47/450) were the most used
antibacterial agents. Patient age (OR, 2.45: 95 % CI: 1.02–5.91: P = 0.024), time-lag between last drug intake and
hospital visit (OR: 3.18: 95 % CI: 1.44–7.0: P < 0.0001), and time-lag between illness onset and hospital visit (OR: 1.89:
95 % CI: 0.38–5.1: P = 0.027) predicted the use of antibacterial agents before hospital visit.
Discussion: Community antibacterial use continues to take place in an unregulated manner. In addition,
physiciansrarely seek to ascertain prior use of antibacterial agents among patients presenting to hospitals. This
couldhave a bearing on patient treatment outcomes.
Conclusion: Knowledge of prior antibacterial use among patients presenting to hospitals is useful to physicians in
ensuring antibacterial stewardship.
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Background
Antibacterial use both in hospital settings and different
communities of the world is increasing exponentially. A
study [1] found that there was a 36 % total increase in
consumption of antibacterial agents globally from 2000
to 2010. The increased global burden of infectious dis-
eases may explain the rise in use of antibacterial drugs
globally [2, 3]. In low income countries, easy over-the-
counter access due to inadequate enforcement or lack of
laws restricting non-prescription sale of antibacterial
agents further influence the increased volume of antibac-
terials consumed [1–4]. This rise in global use of anti-
bacterial agents has been found to be associated with
corresponding increase in development and spread of
resistance [5, 6].
The use of antibacterial agents prior to hospital visit is
common especially in developing countries and has the
potential of influencing patient treatment outcomes [6, 7].
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Assessment of body fluids like plasma using chromato-
graphic methods such as high performance liquid chroma-
tography (HPLC) can help in establishing prior drug use
among patients. However the high associated cost in
addition to the technical expertise required limits its use
as a point of care technique for establishing prior antibac-
terial use especially in resource constrained countries like
Uganda. In most developing countries, health workers rely
on self-report in assessing antibacterial use among pa-
tients prior to hospital visit, information critical for appro-
priate therapeutic choices. The high illiteracy levels in
addition to recall bias reduces the effectiveness of self-
report [8–10]. Previous studies have reported cheap and
reliable method of measuring prior antibacterial use
among patients who visit hospitals in developing countries
using urine antibacterial activity bioassay [11, 12].
The use of non-prescription antibacterial agents before
seeking professional medical treatment is widespread in
most communities Worldwide [4]. In this study, we
assessed the prevalence and predictors of prior antibac-
terial use among out-patients in northern Uganda using
questionnaire technique and urine antibacterial bioassay.
Methods
Ethics statement
The study protocol was reviewed and approved by the
School of Medicine, Makerere University research and
ethics review committee (REC REF 2012–072), and
Uganda National Council for Science and Technology
(HS 126). Permission was obtain from the administra-
tion of the two hospitals. All selected patients provided
written informed consent.
Study design, site and population
This was a cross sectional study among adult (≥18 years)
patients presenting to general out-patient departments
of Lira and Gulu Regional Referral Hospitals (RRHs) in
northern Uganda. Lira RRH is a 415 bed public hospital
serving a population of over 2.5 million people and is
located in central northern Uganda about 375 km from
the capital city Kampala. The hospital receives approxi-
mately 131,296 patients annually in the general out-
patient department. Gulu RRH is a 397 bed public
hospital serving a population of over 1.5 million people
and is located about 364 km from the capital city
Kampala. The hospital receives approximately 77,128
patients annually in the general out-patient department.
Sampling criteria
For each day of data collection, the first patient to be re-
cruited into the study was randomly chosen from among
the patients waiting to be seen in the general outpatient
departments using systematic random sampling. In Lira
and Gulu RRHs, intervals of 14 and 23 were used
respectively to randomly select subsequent patients to
approach for recruitment in the study.
Questionnaire and data collection
Data collection for the study was carried out in 3 months
from August-to-October 2013 in northern Uganda. Data
on use of antibacterial agents at home prior to hospital
visit was collected using a structured interviewer adminis-
tered questionnaire. Information from previous studies
was used in developing the data collection tool. The tool
was pre-tested on 20 patients presenting to out-patient
department of mulago national referral hospital in
Kampala city. The questionnaire was administered by four
trained pharmacy technicians of Lira and Gulu regional
referral hospitals. The questions which were asked in-
cluded; i) What is your age, occupation, sex, and level of
education?, ii) How long did you take since you first felt
the symptoms of the current illness before you came to
the hospital today?, iii) Before coming to the hospital
today, did you take any medicine at home for the current
illness?, iv) If yes, why did you first treat yourself at home
before coming to the hospital?, v) What was the name of
the medicine(s) which you were taking before coming to
the hospital?, vi) What was the color and formulation
(tablet, capsule or others) of the medicine (s) which you
took at home before coming to the hospital?, vii) If more
than one, were you taking them concurrently?, viii) What
was the name of the disease symptom that the antibacter-
ial drug was used to manage?, ix) When did you last take
this antibacterial agent (s) before coming to the hospital?,
x) Who initiated or recommended the use of this antibac-
terial agent (s) that you took at home prior to hospital
visit?, xi) What was the source of the antibacterial agent
(s) that you took at home before coming to the hospital
today?, xii) Did you take more than one type of antibacter-
ial agent to treat yourself at home before coming to the
hospital today?.
The interviews lasted between 15–30 min per patient.
The patients were then requested to collect spontan-
eously voided urine in wide mouth sterile containers.
The urine antibacterial activity bioassays were performed
immediately upon receipt of the sample.
Urine antibacterial bioassay
Urine antibacterial bioassay was performed using a
modified method [11], Bacillus subtilis was used instead
of B. stearothermophilus due to the ease of incubation of
B. subtilis as opposed to B. stearothermophilus. Two
culture media; Mueller Hington II (MHT 20500) agar
(Escherichia coli and Bacillus subtilis) and 5 % sheep
blood agar (Streptococcus pyogenes) were used to deter-
mine the inhibitory activity of patients’ urine against
standard bacterial strains obtained from the American
Type Culture Collection (ATCC; Rockville). Standard
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discs (6 mm diameter) were cut from Whatman filter
paper No.1 and autoclaved together with the cotton
tipped swabs for 15 minutes at 121 °C. Lyophilized test
organisms, Bacillus subtilis, E. coli and S. pyogenes were
cultured. Bacterial colonies from each of the cultured
standard organisms were suspended in 0.85 % sodium
chloride solution and the turbidity adjusted to 0.5
McFarland units. A sterile cotton tipped swab was
dipped in the bacterial suspension and evenly streaked
onto the culture media for the respective reference or-
ganisms. Each Petri dish was marked with numbers 1, 2,
3, 4 and 5 (all along the outer edge of the plate) and 6 at
the centre. The plain sterile filter paper discs were com-
pletely immersed in urine using sterile forceps. Excess
urine was removed and the discs firmly pressed onto the
agar surface corresponding to the marked positions. The
five positions marked on the outer edges of each petri dish
corresponded to urine for different patients. Each sample
was plated in duplicate on separate petri dishes. A blank
filter paper disc was pressed at position 6 in the centre of
both petri dishes as a negative control. The plates were
then incubated at 35–37 °C for 24 h after which the zones
of inhibition were measured. The zone diameter was read
as zero if bacterial growth extended up to the disk. If one
or both duplicate filter paper discs for each reference
organism had a visible zone of inhibition the patient was
recorded as having urinary antibacterial activity. Urine
samples with visible signs of faecal contamination were
excluded from the bioassay. The diameters of the zone
of inhibition were measured using a tape measure and
expressed as the mean of duplicate readings [13]. Urine
antibacterial activity was defined as presence of a zone of
inhibition in any one of the duplicate urine culture plates.
A control media plate was incubated at 37 °C overnight
to check for sterility before the plates were used. Fresh
suspensions of the ATCC indicator bacteria (ATCC 6051,
ATCC 25922, and ATCC 19615) were made and used
each time to avoid contamination. At the beginning of the
study, the indicator organisms were subjected to the com-
monly used antibacterial agents; ampicillin, ciprofloxacin,
gentamicin, augmentin, cotrimoxazole, chloramphenicol,
tetracycline, penicillin, erythromycin and ceftriaxone.
Kirby-Bauer disc diffusion method on Mueller Hington
agar following CLSI guidelines was used [14].
Data management
Double data entry of questionnaire information was
done using Epi Info 3.5.2 (Epi Info, National Centre for
Public Health Informatics, Centres for Diseases Control,
USA). Laboratory data on the diameters of the zones of
inhibition was also entered in duplicate in Excel spread
sheet, 2007. The entries were then merged together in
STATA 12.0. Any discrepancies in the entries were re-
solved by referring to the source documents.
Statistical analysis
Proportions, means and standard deviations were used to
describe the study characteristics. The dependent variable
was urine antibacterial activity. Factors associated with
urine antibacterial activity among the patients were esti-
mated using chi square statistics for categorical variables
and t-test for continuous variables.
Logistic regression was used to determine the predic-
tors of urine antibacterial activity among the patients
presenting to general out-patient departments of Lira
and Gulu RRHs in northern Uganda. The independent
variables considered included, socio-demographic fac-
tors, self-reported antibacterial use, time of last antibac-
terial intake prior to hospital visit, time-lag between the
onset of disease symptoms and hospital visit, the kind of
antibacterial drug used before hospital visit and how it
was taken. The proportions of responses were estimated
using STATA 12.0. In uni-variable models, each inde-
pendent variable was regressed with the outcome vari-
able to determine the crude associations at 95 % level of
significance.
All factors which were significant (P < 0.05) were con-
sidered in the multivariable model to determine joint
predictors of urine antibacterial activity. The model was
built using forward fitting algorithm and goodness-of-fit
determined using Hosmer-Lemeshow test. Wald test
was performed to determine the joint significance of the
explanatory variables in the final multivariable model.
Patients who reported having used only metronidazole
were excluded from the estimation of the correlation be-
tween questionnaire technique and urine antibacterial
activity. This is because their urine samples did not
show any antibacterial activity against the ATCC bacter-
ial strains used in the bioassay [15].
Results
Socio-demographic characteristics of the respondents
In this study, 450 participants were interviewed and
each provided a urine sample for the antibacterial ac-
tivity bioassay. The majority of respondents (342/450,
76 %) were females. The mean age of the participants
was 33.3 ± 13.6 years. One hundred thirty six of the
respondents, 30.2 % (136/450) were engaged in un-
skilled labour and 48.4 % (218/450) lacked formal
education (Table 1).
Antibacterial agents used by participants prior to coming
to the hospital
The commonly used antibacterial agents included metro-
nidazole 15.6 % (70/450), amoxicillin 12 % (54/450), cipro-
floxacin 10.4 % (47/450), doxycycline 6 % (27/450) and
cotrimoxazole 4.9 % (22/450). Public health facilities
51.8 % (233/450), drug shops/pharmacies 31.3 % (141/
450) and clinics 16.7 % (75/450 were the major sources of
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antibacterial agents used. The advice for using antibacter-
ial agents prior to hospital visit was commonly obtained
from health professionals 71.8 % (323/450), drug sellers
18.9 % (85/450), self 8.4 % (38/450) and household mem-
ber 4.2 % (19/450).
Prevalence and factors associated with use of
antibacterial agents prior to hospital visit
Of the 450 respondents, 62.2 % (280) reported using
antibacterial agents from home before visiting the hos-
pital. The most reported disease symptoms which led to
home treatment were mild illness with (112/450: 24.9 %)
or without (238/450: 52.9 %) fever. While, successful ex-
perience in treatment of previous illness was the most
common reason (130/450: 28.9 %) for taking antibacter-
ial drugs at home prior to hospital visit.
Urine antibacterial bioassay against E. coli, B. subtilis and
S. pyogenes
Antibacterial activity was demonstrated on at least one of
the three standard test bacterial strains in 30.4 % (137/
450) of the urine samples. The growth of Bacillus subtilis
was inhibited by 25.1 % (113/450) of the urine samples
with the mean zone of inhibition being 3.6 ± 6.9 mm.
Most of the urine samples with antibacterial activity
against B. subtilis, 85.8 % (97/113) had a smaller zone of
inhibition (1 mm), and 12.4 % (14/113) had a medium
zone of inhibition (21 mm) while 1.8 % (2/113) had a lar-
ger zone of inhibition (≥31 mm). For E. coli, growth was
inhibited by 20.9 % (94/450) of the urine samples with
mean inhibition zone diameter of 2.8 ± 6.4 mm. Of the
urine samples with antibacterial activity against E. coli,
80.9 % (76/94) had a smaller zone of inhibition, 18.1 %
(17/94) had a medium zone of inhibition while 1.1 % (1/
94) had a larger zone of inhibition. For S. pyogenes growth
was inhibited by 16.7 % (75/450) of the urine samples with
mean inhibition zone diameter of 3.2 ± 8 mm. Of the
urine samples with antibacterial activity against S. pyo-
genes, 56 % (42/75) had a smaller zone of inhibition,
34.7 % (26/75) had a medium zone of inhibition while
9.3 % (7/75) had a larger zone of inhibition.
The patients who reported use of antibacterial drugs
prior to hospital visit had more urine samples with
higher zones of inhibition than those who did not
report use of antibacterial drugs before visiting the
hospital. Among the patients who reported taking anti-
bacterial drugs prior to hospital visit and who had a
positive urine antibacterial assay (n = 137), 62 % (85)
reported using more than one antibacterial agent at
home prior to visiting the hospital. Thirty six (8 %)
urine samples had antibacterial activity on only one
organism, 57 (12.7 %) on two organisms while 44
(9.8 %) were positive on all three strains of the test
organisms. Of the 85 urine samples from patients who
reported not to have taken antibacterial agents prior
to hospital visit, 18.8 % (16/85) had positive antibac-
terial activity (Fig. 1).
Factors associated with urine antibacterial activity
In the multivariable model, the age of study partici-
pants was significantly associated with urine antibac-
terial activity with those who were 48–57 years of age
had two times more positive urine antibacterial activ-
ity compared to 18–27 year old participants (OR,
2.45: 95 % CI: 1.02–5.91: P = 0.024). Patients who re-
ported taking medicines at home on the same day of
hospital visit had three times more urine antibacterial
activity (OR: 3.18, 95 % CI: 1.4–7.0, P < 0.0001) than
those who did not (Table 2). The model fitted with
Hosmer-Lemeshow (H-L) probability of 0.92 (P = 0.92)
on ten (10) groups.
In all the urine culture plates there was no
observable inhibition of bacterial growth by the blank
filter paper discs which were pressed at the centre of
each plate as negative controls during the antibacterial
activity bioassay. In addition, the ATCC bacterial
strains used in the urine antibacterial activity bioassays
were all sensitive to the commonly used antibacterial
agents.
Table 1 Demographic characteristics of the respondents and
urine antibiotic activity
Factor Description Number of
participants,
(N = 450; %)
Number of urine
samples with antibiotic
activity (N = 137; %)
P-value
Sex Female 342 (76 %) 106 (77.4 %) 0.652
Male 108 (24 %) 31 (22.6 %)
Age (years) 18–27 199 (44.2 %) 43 (31.4 %) 0.008
28–37 102 (22.7 %) 38 (27.7 %)
38–47 81 (18 %) 32 (23.4 %)
48–57 34 (7.6 %) (9.5 %)
≥58 34 (7.6 %) 11 (8.0 %)
Occupation Unskilled
labour
136 (30.2 %) 48 (35.0 %) 0.371
Professional 87 (19.3 %) 22 (16.1 %)
Business
owner
48 (10.7 %) 17 (12.4 %)
Others 179 (39.8 %) 50 (36.5 %)
Education
level
None 218 (48.4 %) 77 (56.2 %) 0.129
Primary
level
131 (29.1 %) 37 (27 %)
Secondary
level
52 (11.6 %) 16 (11.7 %)
Tertiary
level
49 (10.9 %) 7 (5.1 %)
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Discussion
The use of antibacterial drugs prior to hospital visit is a
potential threat to patient care and is a common practice
in many resource limited communities globally. In this
study, a third of the urine samples tested had positive anti-
bacterial activity indicating prior antibacterial exposure
among out-patients presenting to the hospitals in north-
ern Uganda. This finding is similar to that of a previous
study done in Nepal [16]. The high prevalence of infec-
tious diseases especially in developing countries, coupled
with easy access over-the-counter influences the volume
of antibacterial agents consumed [2, 17]. A previous study
[18] found a high prevalence of non-prescription use of
antibacterial agents in communities of northern Uganda.
This coupled with the high prescription of antibacterials
in hospitals especially in low income countries in addition
to potential exposure through consumption of animal and
agricultural products creates drug pressure in communi-
ties which potentially increase the risk of resistance devel-
opment [5, 17, 19]. Although antibacterial resistance can
develop irrespective of whether the drug is used
appropriately or not, the risk is likely to be higher
when used inappropriately, a practice common in
self-medication [20, 21]. Establishing trends in antibac-
terial consumption is key in understanding the epidemi-
ology of resistance. This can help predict the threat of
resistance in patient care, establish initiatives to preserve
efficacy of antibacterial agents and provide baseline data
for the assessment of efforts for future reduction in com-
munity consumption of antibacterial agents [1, 22, 23].
The high proportion of female respondents found in
this study could be attributed to their generally better
healthcare seeking behaviour [24]. Earlier studies have
reported past experiences as a main determinant of anti-
bacterial self-medication especially in resource limited
countries [25, 26]. In this study, the likelihood of taking
antibacterial agent prior to hospital visit increased with
increase in age beyond 18 years. This could be due to
the accumulated experiences in the treatment of infec-
tious diseases which are highly prevalent in this settings
[23]. The longer the time-lag between reported onset of
illness and hospital visit, the more likely for patients to
Fig. 1 Study flow chart
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have positive urine antibacterial activity indicating prior
exposure. Most patients spent more than a week taking
antibacterial drugs at home before visiting the hospital.
A third of the deaths (33 %) in a South African study as-
sociated to malaria were due to delays of three or more
days before seeking professional medical treatment [21].
A previous study [27] reported that patients were
generally unwilling to disclose information on their non-
prescription use of antibacterial agents. In addition, phy-
sicians rarely explore to establish existence of prior
antibacterial use among patients presenting to hospitals
for healthcare. This was shown by our findings in which
some patients who reported not to have taken any anti-
bacterial prior to hospital visit were found to have urine
with antibacterial activity. Patients are thus likely to be
prescribed antibacterial agents which they have already
tried at home before coming to the hospital. This is
likely especially due to the limited therapeutic choices in
this settings and could increase the risk of treatment
failure which potentially affects patient trust and confi-
dence in the physicians and the healthcare system.
Therefore assessment of antibacterial use prior to hos-
pital visit among patients is a useful practice in ensuring
antibacterial stewardship. This can be achieved using
both qualitative and quantitative methods. The use of
urine antibacterial bioassay is a valuable and affordable
tool for assessment of prior antibacterial use among
patients presenting to hospital before initiating any treat-
ment especially in resource limited communities [11].
The study found that questionnaire technique esti-
mated a higher prevalence of antibacterial use prior
to hospital visit among out-patients compared to
urine antibacterial assay, contrary to findings of previ-
ous studies [11]. Most patients reported to have used
metronidazole, amoxicillin, ciprofloxacin, doxycycline
and cotrimoxazole prior to hospital visit. This was
consistent with the bioassay findings in which more
urine samples from patients who reported to have
taken antibacterial drugs had antibacterial activity
with larger zones of inhibition. The absence of anti-
bacterial activity of the urine samples of some patients
who reported to have taken antibacterial drugs prior to
hospital visit could be attributed to the uncertainty be-
tween actual dose, dosing time and when sample collec-
tion was performed. In addition, the lack of awareness by
patients regarding the exact kind of medicine which was
taken may have contributed to the urine antibacterial bio-
assay findings in this study. Furthermore, the quality of
antibacterial drugs may also affect the urine antibacterial
activity as high prevalence of substandard antimicrobial
agents especially in developing countries has been previ-
ously reported [28]. The high level of illiteracy in northern
Uganda, a region which suffered more than two decades
of armed conflict potentially affects patients recall in
Table 2 Factors associated with urine antibacterial activity
Variable Description Proportion with urine
activity (n = 137)
Crude OR (95%CI) Adjusted OR (95%CI) P-value
Patient age (years) 18–27 43 (31.4 %) 1.0 1.0 0.024
28–37 38 (27.7 %) 2.15 (1.27–3.64) 2.20 (1.24–3.90)
38–47 32 (23.4 %) 2.37 (1.35–4.14) 2.23 (1.20–4.13)
48–57 13 (9.5 %) 2.25 (1.04–4.45) 2.45 (1.02–5.91)
58+ 11 (8.1 %) 1.74 (0.78–3.84) 2.02 (0.81–5.01)
Duration of time of last drug
intake prior to hospital visit
Did not take any
antibacterial
16 (11.7 %) 1.0 1.0 <0.0001
Today 51 (37.2 %) 4.07 (2.09–7.92) 3.18 (1.44–7.00)
2–4 days ago 45 (32.8 %) 2.81 (1.45–5.45) 1.81 (0.82–4.03)
5–7 days ago 1 (0.7 %) 0.25 (0.03–2.05) 0.16 (0.02–1.37)
8–30 days ago 18 (13.1 %) 1.92 (0.86–4.27) 1.40 (0.55–3.55)
Do not remember 16 (11.7 %) 0.51 (0.20–1.26) 0.41 (0.16–1.08)
Duration of time between first
illness onset and hospital visit
Today 3 (2.2 %) 1.0 1.0 0.027
2 days ago 5 (3.6 %) 0.21 (0.04–1.12) 0.1 (0.08–0.57)
A week ago 36 (26.3 %) 2.1 (0.31–4.2) 1.03 (0.25–4.2)
More than a week 93 (67.9 %) 2.4 (0.47–6.0) 1.89 (0.38–5.1)
Used more than one type of drug
at home prior to hospital visit
No 12 (9.8 %) 1.0 1.0 0.05
Yes 61 (44.5 %) 2.46 (1.63–3.71) 1.6 (0.9–2.7)
OR Odds Ratio, CI Confidence Interval
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addition to inadequate labelling of packaging materials
from drug outlets [8, 29, 30]. The findings of our study are
useful to physicians, the community and policy makers as
it provides evidence of prior antibacterial use among
patients seeking treatment in hospitals and can be used
in informing antibacterial stewardship strategies among
health professionals and the communities in northern
Uganda.
The study had some limitations high level of illiteracy in
the region might have affected patient recall. Urine anti-
bacterial activity depends on rate, extent of urine excre-
tion, the timing of urine collection and is dependent on
the sensitivity of ATCC bacterial strains used against com-
monly used antibacterial agents. Measurement of actual
antibacterial drug concentrations in blood or urine using
HPLC would be a preferable method of establishing prior
antibacterial use however associated high cost and tech-
nical requirements would limit its application at point of
care for routine assessment of prior antibacterial use espe-
cially in resource limited settings of developing countries.
Conclusion
A third of the patients presenting to the general out-
patient departments of hospitals in northern Uganda
have taken antibacterial agents prior to hospital visit.
Knowledge of prior antibacterial use among patients
presenting to hospitals is useful to physicians in ensuring
antibacterial stewardship.
Abbreviation
CLSI: Clinical Laboratory Standards Institute; ATCC: American type culture
collection; HPLC: High performance liquid Chromatography; RRH: Regional
Referral Hospital; REC REF: Review committee reference; OR: Odds ratio;
CI: Confidence interval.
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